FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
−0.27%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- —
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.21
- EPS estimate
- -$0.24
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +6.5%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.24 | -$0.21 | Beat 13.69% | — |
| Apr 27, 2026 | -$0.31 | -$0.25 | Beat 19.35% | — |
| Feb 24, 2026 | -$0.31 | -$0.31 | In line | — |
| Oct 29, 2025 | -$0.29 | -$0.31 | Miss -6.90% | — |
| Jul 29, 2025 | -$0.29 | -$0.28 | Beat 3.45% | — |
| May 1, 2025 | -$0.29 | -$0.28 | Beat 3.45% | — |
| Jul 31, 2024 | $0.01 | $0.87 | Beat 7060.49% | $80.0M |
| Feb 27, 2024 | -$0.44 | -$0.40 | Beat 9.09% | $871.0K |
| Aug 3, 2023 | -$0.44 | -$0.38 | Beat 13.64% | $880.0K |
| Jun 23, 2023 | — | -$0.45 | — | $685.0K |
| Aug 11, 2022 | -$0.66 | -$0.83 | Miss -25.76% | $1.9M |
| Mar 3, 2022 | -$0.65 | -$0.58 | Beat 10.77% | $5.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026